Soligenix receives U.S. patent for dusquetide related analogs
Soligenix announced that the USPTO will issue a new patent that claims composition of matter for novel innate defense regulator analogs, expanding patent protection to more diverse analog structures. Therapeutic use claims in oral mucositis, colitis, and infectious disease, both alone and in conjunction with antibiotics, will also issue. Dusquetide, the active ingredient in SGX942, demonstrated positive results in a Phase 2 study in the treatment of oral mucositis in head and neck cancer patients. In addition to the oral mucositis findings, an increased incidence of "complete response" of tumor at the one month and 12-month follow-up visits were observed. Decreases in infection rate and an increase in the 12-month survival rate were also observed with SGX942 treatment. SGX942 is currently being evaluated in a pivotal, Phase 3, randomized, double-blind, placebo-controlled, multinational clinical study for the treatment of oral mucositis in HNC patients. The ongoing Phase 3 trial is actively enrolling patients in the US and Europe.